ArticleThoracic cancer2023
Knockdown of circADAM9 inhibits cell progression and glycolysis by targeting the miR-1236-3p/FGF7 axis in breast cancer.
Article in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Time- and dose-dependent regulation of circular RNAs in the response of triple-negative breast cancer cells to ionizing radiation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Exploratory Analysis of Circulating Serum miR-197-3p, miR-1236, and miR-1271 Expression in Early Breast Cancer.International journal of molecular sciences · 2025Article
- Exosomal circRNAs: key modulators in breast cancer progression.Cell death discovery · 2025Review
- Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA.Thoracic cancer · 2024Article
- Fibroblast growth factor pathway promotes glycolysis by activating LDHA and suppressing LDHB in a STAT1-dependent manner in prostate cancer.Journal of translational medicine · 2024Article
- Knockdown of circADAM9 inhibits cell progression and glycolysis by targeting the miR-1236-3p/FGF7 axis in breast cancer.Thoracic cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCircular RNAs (circRNAs) are closely associated with the development of breast cancer (BC). In this study, we aimed to clarify how differentially expressed circRNAs affect the development of BC.
methodsQuantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of circADAM9, miR-1236-3p and fibroblast growth factor 7 (FGF7). Colony formation, 5-ethynyl-2'-deoxyuridine (EdU), wound healing, transwell, and flow cytometry were used to assess cell proliferation, migration, invasion, and apoptosis. Glucose consumption, lactic acid production and ATP levels were assessed using glycolysis metabolism analysis. Dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay were carried out to verify the relationship between miR-1236-3p and circADAM9 or FGF7. The roles of cirADAM9 on tumor growth were analyzed using a xenograft tumor model. Ki-67 and FGF7 expression was measured via immunohistochemistry (IHC) assay. Apoptosis-related proteins and exosome markers were detected by western blot.
resultsCircADAM9 was highly expressed in BC cells, and circADAM9 silencing inhibited BC cell proliferation, migration, invasion, and glycolysis, and promoted cell apoptosis. Furthermore, miR-1236-3p inhibition could overturn circADAM9 knockdown-mediated BC inhibition. Moreover, the negative influences of miR-1236-3p overexpression on BC progression were restrained via FGF7 overexpression. CircADAM9 silence also inhibited BC tumor growth in vivo.
conclusionCircADAM9 promoted BC development partly by the miR-1236-3p/FGF7 axis, highlighting a potential prognostic biomarker and therapeutic target for BC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.